TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Uniphar PLC ( (GB:UPR) ) just unveiled an update.
Uniphar PLC reported a strong performance in the first half of 2025, with double-digit adjusted EPS growth, driven by an 8% organic gross profit growth and reduced finance costs. The company completed a €35 million share buyback and maintained a strong liquidity position with a Net Bank Debt/EBITDA of 1.9x. Uniphar’s divisions showed varied growth, with Pharma achieving double-digit, Medtech high single-digit, and Supply Chain & Retail low single-digit organic gross profit growth. The company remains optimistic about its growth trajectory, supported by declining interest rates and a disciplined M&A strategy, aiming for a €200 million EBITDA target by 2028.
More about Uniphar PLC
Uniphar PLC is an international diversified healthcare services business. It operates in the pharmaceutical, medtech, and supply chain & retail sectors, focusing on delivering healthcare solutions and services across these industries.
See more insights into UPR stock on TipRanks’ Stock Analysis page.